X0508 4 2026-02-21 0001750149 Inhibikase Therapeutics, Inc. IKT 0001814928 Cabell Christopher 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 false true false false President & Head of R&D false Common Stock 2026-02-21 4 D false 338282 0 D 676564 D As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture. /s/ Mark Iwicki, attorney-in-fact 2026-02-24